Kevin Dinnell

USPTO Granted Patents = 15 (Patent Applications = 2)

CIPO Patents = 1

EPO Patents = 5 (Patent Applications = 3)

Average Co-Inventor Count = 4.3

ph-index = 3

Forward Citations = 34(Granted Patents)

Location History:

Much Hadham, GB (2002 - 2009)
Harlow, GB (2003 - 2014)

Company Filing History:

10 out of 2,405

Merck Sharp + Dohme Corp.

where one patent can have more than one assignee

Years Active: 2002-2014

Loading Chart...

15 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 8829031 - Indole derivative modulators of the alpha 7 nAChR (2014-09-09),

2. 8796283 - Indole and azaindole modulators of the alpha 7 nachr (2014-08-05),

3. 8377941 - Indoles as modulators of nicotinic acetylcholine receptor subtype alpha-7 (2013-02-19),

4. 8283365 - Indole modulators of the alpha 7 nicotinic acetylcholine receptor (2012-10-09),

5. 7598386 - Sulphones which modulate the action of gamma-secretase (2009-10-06),

6. 7595344 - Sulphones which modulate the action of gamma secretase (2009-09-29),

7. 7410964 - Cyclohexyl sulphones as gamma-secretase inhibitors (2008-08-12),

8. 7342009 - Cyclic sulfonamides for inhibition of gamma-secretase (2008-03-11),

9. 7304094 - Cyclohexyl sulphones (2007-12-04),

10. 7253205 - Gem-disubstituted cyclohexane derivatives and their use as therapeutic agents (2007-08-07),

11. 7105507 - Cyclohexane derivatives and their use as therapeutic agents (2006-09-12),

12. 6984663 - Cyclohexyl sulphones (2006-01-10),

13. 6953792 - Cyclohexyl derivatives and their use as therapeutic agents (2005-10-11),

14. 6518273 - 2-aryl indole derivative as antagonists of tachykinins (2003-02-11),

15. 6476045 - Azaindole derivatives and their use as therapeutic agents (2002-11-05),

Title: Kevin Dinnell: A Visionary Inventor in Neuropharmacology

Introduction: Kevin Dinnell, a renowned inventor based in Much Hadham, GB, has made significant contributions to the field of neuropharmacology with a total of 15 patents to his name. His innovative work primarily focuses on the modulation of the nicotinic acetylcholine receptor (nAChR), which plays a crucial role in various neurological processes.

Latest Patents: Among his latest inventions are two notable patents. The first, titled "Indole Derivative Modulators of the Alpha 7 nAChR," pertains to the modulation of the α7 nicotinic acetylcholine receptor by a specific compound formula. This compound includes groups such as imidazolyl, pyridinyl, or pyrimidinyl, which can be further substituted by various alkyl and alkoxy groups. The second patent, "Indole and Azaindole Modulators of the Alpha 7 nAChR," also centers around the α7 nAChR, presenting a similar compound formula relevant to pharmaceutical applications.

Career Highlights: Kevin has had a remarkable career, demonstrating his expertise and dedication to advancing medical science. He has been associated with prominent organizations such as Merck Sharp & Dohme Corporation and Proximagen Limited, where he has played a pivotal role in research and development.

Collaborations: Throughout his journey, Kevin has collaborated with esteemed colleagues, including Duncan Edward Shaw and Timothy Harrison. These partnerships have further enhanced his research capabilities and contributed to the success of his inventions.

Conclusion: Kevin Dinnell stands out as an influential inventor in the pharmaceutical industry, particularly in neuropharmacology. His innovative contributions, notably in the modulation of nicotinic acetylcholine receptors, are paving the way for new therapeutic options and improving understanding of neurological conditions. With a strong portfolio of patents and collaborations, he continues to inspire future innovations in science and medicine.

This text is generated by artificial intelligence and may not be accurate.